Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 18/2003

01-12-2003 | Review Article

The health economics of bladder cancer

A comprehensive review of the published literature

Authors: Marc F. Botteman, Chris L. Pashos, Alberto Redaelli, Benjamin Laskin, Robert Hauser

Published in: PharmacoEconomics | Issue 18/2003

Login to get access

Abstract

The aim of this paper was to conduct a critical systematic review of the available literature on the clinical and economic burden of bladder cancer in developed countries, with a focus on the cost effectiveness of interventions aimed at reducing that burden.
Forty-four economic studies were included in the review. Because of longterm survival and the need for lifelong routine monitoring and treatment, the cost per patient of bladder cancer from diagnosis to death is the highest of all cancers, ranging from $US96 000–187 000 (2001 values) in the US. Overall, bladder cancer is the fifth most expensive cancer in terms of total medical care expenditures, accounting for almost $US3.7 billion (2001 values) in direct costs in the US.
Screening for bladder cancer in the general population is currently not recommended. The economic value of relatively new and less expensive urine assays and molecular urinary tumour markers has not been assessed. However, the literature suggests that screening patients suspected of having bladder cancer and using less invasive diagnostic procedures is cost effective.
Very few cost-effectiveness studies have evaluated intravesical therapies such as bacillus Calmette-Guérin and mitomycin in the management of superficial disease and no robust recommendations can be drawn. Economic analyses suggest that non-surgical treatment strategies for the management of invasive disease aiming at bladder preservation may not be cost effective, because they have not consistently demonstrated survival benefits and do not eliminate the need for subsequent radical cystectomy.
The literature suggests that the current conventional frequent follow-up and monitoring of patients can be cost effectively replaced by less frequent and less invasive monitoring, and should rely more heavily on intravesical chemotherapy to reduce the need for cystoscopies.
Bladder cancer is a fairly common and costly malignancy. Nevertheless, the existing literature only contributes marginally to our knowledge concerning the burden of bladder cancer and the economic value of various interventions. The limited value of the literature in this area may be attributed to (i) being published as abstracts rather than full peer-reviewed evaluations; (ii) employing questionable methodologies; and (iii) being in many cases nearly obsolete, rendering them less relevant to, if not in conflict with, current clinical practice. Consequently, opportunities exist to conduct meaningful economic research in all areas of the management of bladder cancer, including screening, diagnosis, follow-up and treatment, especially with respect to new and innovative pharmaceutical and other technologies.
Literature
1.
Ferlay J, Bray F, Pisani P, et al.. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. Lyon: IARC Press, 2001
2.
Miller BA, Kolonel LN, Bernstein L, et al. Racial/ethnic patterns of cancer in the United States 1988–1992. Bethesda (MD): National Cancer Institute; 1996. NIH Pub. No. 96-4104
3.
National Cancer Institute. NCI fact book. Bethesda, (MD): National Institutes of Health; 2000. NIH Pub. No. 01-512
4.
Marcus PM, Hayes RB, Vineis P, et al. Cigarette smoking, Nacetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000; 9 (5): 461–7PubMed
5.
Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13 (5): 291–8PubMedCrossRef
6.
Metts MC, Metts JC, Milito SJ, et al. Bladder cancer: a review of diagnosis and management. J Nall Med Assoc 2000; 92 (6): 285–94
7.
Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control 2000; 7 (4): 335–9PubMed
8.
Dalbagni G, Herr HW. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am 2000; 27 (1): 137–46PubMedCrossRef
9.
Lee R, Droller MI. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000; 27 (1): 1–13, viiPubMedCrossRef
10.
Kurth KH, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumours. Fur J Cancer 1995; 31A (11): 1840–6
11.
Young MJ, Soloway MS. Office evaluation and management of bladder neoplasms. Urol Clin North Am 1998; 25 (4): 603–11PubMedCrossRef
12.
Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am 2000; 27 (1): 125–35, xPubMedCrossRef
13.
Zietman AL, Shipley WU, Kaufman DS. Organ-conserving approaches to muscle-invasive bladder cancer: future altemalives to radical cystectomy. Ann Med 2000; 32 (1): 34–42PubMedCrossRef
14.
Brown ML, Fintor L. The economic burden of cancer. In: Greenwald P, Kramer BS, Weed DL, editors. Cancer prevention and control. New York: Marcel-Dekker, 1995: 69–81
15.
Salkeld G, Morrell S, Webster F, et al. Economic cost of health, effects of occupational exposure to hazardous substances. Australia: National Occupational Health & Safety Commission, 1996
16.
Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33 (8): 828–41PubMedCrossRef
17.
Baker S, Kessler LG, Smucker RC. Site-specific treatment costs for cancer: an analysis of the Medicare Continuous History Sample file. In: Scheffler RM, Andrews NC, editors. Cancer care and costs: DRG’s and beyond 1989. Ann Arbor (MI): Health Administration Press Perspectives, 1989
18.
AN Associates Inc. Cost of illness handbook. Washington, DC: United States Environmental Protection Agency, Office of Pollution Prevention and Toxics, 2001
19.
Ruttenberg R, Powers M. Economics of notification and medical screening for high-risk workers. J Occup Med 1986; 28 (8): 757–64PubMedCrossRef
20.
Han M, Schoenberg MP. The use of molecular diagnostics in bladder cancer. Urol Oncol 2000; 5 (3): 87–92PubMedCrossRef
21.
Ellwein LB, Farrow GM, Friedell GH, et al. An assessment of the impact of urine cytology screening using a computer-based model of bladder cancer. Urol Clin North Am 1984; 11 (4): 585–98PubMed
22.
Messing EM, Young TB, Hunt VB, et al. Hematuria home screening: repeat testing results. J Urol 1995; 154 (1): 57–61PubMedCrossRef
23.
Brausi M, Ferretti S. Screening for asymptomatic microscopic hematuria (MA) in a health population: results of a study of 2065 individuals [abstract]. J Urol 2000; 163 (4 Suppl.): 3
24.
Ellison LM, Ellsworth PI, Birkmeyer JD. Cost-effectiveness of screening for bladder cancer after radiation therapy for prostate cancer [abstract]. J Urol 2000; 163 (4 Suppl.): 3
25.
Burchardt M, Burchardt T, Shabsigh A, et al. Current concepts in biomarker technology for bladder cancers. Clin Chem 2000; 46 (5): 595–605PubMed
26.
Cummings KB, Barone JG, Ward WS. Diagnosis and staging of bladder cancer. Urol Clin North Am 1992; 19 (3): 455–65PubMed
27.
Corwin HL, Silverstein MD. The diagnosis of neoplasia in patients with asymptomatic microscopic hematuria: a decision analysis. J Urol 1988; 139 (5): 1002–6PubMed
28.
Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999; 161 (1): 62–5PubMedCrossRef
29.
Zippe C, Pandrangi L, Potts JM, et al. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res 1999; 19 (4A): 2621–3PubMed
30.
Hansen MV, Zdanowski A. The agreement among urological experts on the diagnostic management of patients with common mological problems. Br J Urol 1997; 80 (5): 787–92PubMedCrossRef
31.
Hunt MT, Woodhouse CR. Cost-effectiveness of investigations for invasive bladder cancer. J R Soc Med 1987; 80 (3): 143–4PubMed
32.
Lindner A, deKernion JB. Cost-effective analysis of pre-cystectomy radioisotope scans. J Urol 1982; 128 (6: 1181–2PubMed
33.
Kiemeney LA, Wiges JA, Heijbroek RP, et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150 (1): 60–4PubMed
34.
Raitanen MP, Tammela TL. Impact of tumour grade, stage, number and size, smoking habits and sex on the recurrence rate and disease-free interval in patients with transitional cell carcinoma of the bladder. Ann Chir Gynaecol 1995; 84 (1): 37–41PubMed
35.
Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164 (3 Pt 1): 680–4PubMedCrossRef
36.
Zlotta AR, Schulman CC. Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am 2000; 27 (1): 179–xiiPubMedCrossRef
37.
Kurth KH, Bouffioux C, Sylvester R, et al. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Fur Urol 2000; 37 Suppl. 3: 1–9
38.
Smith Jr JA, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, TI and TIS): The American Urological Association. J Urol 1999; 162 (5): 1697-701PubMedCrossRef
39.
Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 2000; 163 (1): 68–71PubMedCrossRef
40.
Birch BR, Anson KM, Miller RA. Sedoanalgesia in urology: a safe, cost-effective alternative to general anaesthesia: a review of 1020 cases. Br J Urol 1990; 66 (4): 342–50PubMedCrossRef
41.
Holmang S, Aldenborg F, Hedelin H. Multiple bladder biopsies under intravesical lignocaine anaesthesia. Br J Urol 1994; 73 (2): 160–3PubMedCrossRef
42.
Hedelin H, Holmang S, Wiman L. Outpatient treatment of bladder cancer: lower cost and satisfied patients. Nord Med 1997; 112 (2): 48–51PubMed
43.
Jewett MA, Valiquette L, Sampson HA, et al. Electromotive drug administration of lidocaine as an alternative anesthesia for transurethral surgery. J Urol 1999; 161 (2): 482–5PubMedCrossRef
44.
Shanberg AM, Marinelli D, Tansey LA, et al. Cost analysis of neodymium-YAG laser versus transurethral resection treatment of superficial bladder carcinoma. Int Surg 1993; 78 (4): 350–1PubMed
45.
Tellez Martinez-Fornes M, Maganto PE, Vallejo III, et al. Treatment of recurrent bladder surface tumors with laser Nd: Yag: a single-year experience. Actas Urol Esp 1993; 17 (1): 35–9
46.
Smith PH. The costs of intravesical chemotherapy. Prog Clin Biol Res 1985; 185B: 39–44PubMed
47.
Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt) 2000; 14 (5): 719–29
48.
Carroll PR, Williams RD, Kim MJ, et al. Mitomycin C reused: an in vitro cost-effectiveness study. J Urol 1984; 132 (3): 583–6PubMed
49.
Kilbridge KL, Kantoff PW, Loughlin KR, et al. Is bacillus calmette-guerin (BCG) immunotherapy cost-effective in recurrent high grade transitional cell cancer (TCC)? [abstract]. J Urol 1997; 157 (4 Suppl.): 214
50.
Marchetti A, Wang L, Magar R, et al. Management of patients with bacilli calmette-guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther 2000; 22 (4): 422–38PubMedCrossRef
51.
Rivera I, Wajsman Z. Bladder-sparing treatment of invasive bladder cancer. Cancer Control 2000; 7 (4): 340–6PubMed
52.
Sternberg CN. Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Semin Oncol 1996; 23 (5): 621–32PubMed
53.
Martinez-Pineiro JA, Martinez-Pineiro L. The role of neoadjuvant chemotherapy for invasive bladder cancer. Br J Urol 1998; 82 (1): 33–42PubMedCrossRef
54.
von der Maase MIL, Hansen SW, Liepa A, et al. Health care resources use for patients with advanced bladder cancer treated with gemcitabine plus cisplatin (GC) versus MVAC in phase III trial [abstract]. Ann Oncol 2000; 11 (4 Suppl.): 74
55.
von der Maase MIL, Hansen SW, Roberts IT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18 (17): 3068–77PubMed
56.
Bredin HC, Prout Jr GR. One-stage radical cystectomy for bladder carcinoma: operative mortality, costibenefit analysis. J Urol 1977; 117 (4): 447–51PubMed
57.
Zenni MK, Griebling TL, Kreder KJ, et al. Impact of preoperative comorbidity on complications and costs in patients undergoing radical cystectomy and orthotopic urinary diversions [abstract]. J Urol 1998; 159 (5 Suppl.): 53
58.
Klein FA, Whitmore Jr WF. Bladder papilloma: therapeutic and cost effect of outpatient department management. Urology 1981; 18 (3): 247–9PubMedCrossRef
59.
Knoblauch NO, Ronning H, Knudsen P, et al. Routine use of ultrasound and flexible cystoscopy in the control of benign bladder tumours. Int Urol Nephrol 1994; 26 (4): 431–6PubMedCrossRef
60.
Hall RR, Parmar MK, Richards AB, et al. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994; 308 (6923): 257–60PubMedCrossRef
61.
Kilbridge KL, Kuntz KM, Kagan AR, et al. The cost-effectiveness (CE) of frequent follow-up (F/U) in superficial transitional cell cancer (TCC) of the bladder [abstract]. Am Soc Clin Oncol 1996; 15: 326
62.
Nam RK, Redelmeier DA, Spiess PE, et al. Comparison of molecular and conventional strategies for follow-up of superficial bladder cancer using decision analysis. J Urol 2000; 163 (3): 752–7
63.
Lachaine J, Valiquette L, Crott R. Economic evaluation of NMP22 in the management of bladder cancer. Can J Urol 2000; 7 (2): 974–80PubMed
64.
Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002; 167 (1): 75–9PubMedCrossRef
65.
The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. The United Kingdom and Eire Bladder Tumour Antigen Study Group. Br J Urol 1997; 79 (3): 362-6
66.
Neymark N, Torts K. Economics of urinary tract cancers: state of the art. Eur Urol 1997; 31 Suppl. 1: 72–81PubMed
Metadata
Title
The health economics of bladder cancer
A comprehensive review of the published literature
Authors
Marc F. Botteman
Chris L. Pashos
Alberto Redaelli
Benjamin Laskin
Robert Hauser
Publication date
01-12-2003
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 18/2003
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/BF03262330